stockrow
Saturday 7 November 2026
Export CTNM’s income statement to Excel — free account
Contineum Therapeutics, Inc.
CTNM Healthcare Biotechnology
Contineum Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $50.0 million.
- EPS
- −8.22%
- Free cash flow
- +10.0%
Quarter to September 2026, against a year earlier
9.42
0.61
+6.92%
Follow CTNM
Alert me
Contineum Therapeutics, Inc. (CTNM) P/E ratio
Contineum Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 1.8× (June 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 1.4× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2023 | 1.4× | — |
Against its own ten years
Low 0.0×
High 1.8×
Ten-year median
0.0×
Current reading's percentile
91
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OBIO Orchestra BioMed Holdings, Inc. compare | n/m |
| AVIR Atea Pharmaceuticals, Inc. compare | n/m |
| CTNM Contineum Therapeutics, Inc. | n/m |
| RZLT Rezolute, Inc. compare | n/m |
| MPLT MapLight Therapeutics, Inc. compare | n/m |
| SRZN Surrozen, Inc. compare | n/m |
| AVTX Avalo Therapeutics, Inc. compare | n/m |
| AGMB AgomAb Therapeutics NV compare | — |
| TRXB TRex Bio Inc. compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)